European equities traded in the US as American depositary receipts kicked off the week on a positive note late Monday morning, rising 0.88% to 1,457.38 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firms Evaxion Biotech (EVAX) and BioNTech (BNTX), which rose 6.3% and 4.2%, respectively. They were followed by petroleum refiner Equinor (EQNR) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which were up 2.9% and 2.4%, respectively.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ), which fell 3.3%, and medical device maker EDAP TMS (EDAP), which lost 1.7%. They were followed by biopharmaceutical company Genfit (GNFT) and accommodation booking company trivago (TRVG), which were down 1.6% and 0.5%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Amarin (AMRN), which advanced 12% and 5.5%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Biodexa Pharmaceuticals (BDRX), which increased 4.3% and 2.4%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies TC Biopharm (TCBP) and NuCana (NCNA), which lost 4.9% and 1.4%, respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Verona Pharma (VRNA), which were off 0.5% each.
Comments